Literature DB >> 32061753

SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.

Chunwan Lu1, John D Klement2, Dafeng Yang2, Thomas Albers3, Iryna O Lebedyeva4, Jennifer L Waller5, Kebin Liu6.   

Abstract

Trimethylation of histone 3 lysine 9 (H3K9me3) at gene promoters is a major epigenetic mechanism that silences gene expression. We have developed a small molecule inhibitor for the H3K9me3-specific histone methyltransferase SUV39H1. We report here that FAS expression is significantly down-regulated and SUV39H1 expression is significantly up-regulated in human colorectal carcinoma (CRC) as compared to normal colon. SUV39H1-selective inhibitor F5446 decreased H3K9me3 deposition at the FAS promoter, increased Fas expression, and increased CRC cell sensitivity to FasL-induced apoptosis in vitro. Furthermore, inhibition of SUV39H1 altered the expression of genes with known functions in DNA replication and cell cycle in the metastatic colon carcinoma cells, which is associated with cell cycle arrest at S phase in the metastatic human colon carcinoma cells, resulting in tumor cell apoptosis and growth inhibition in a concentration-dependent manner in vitro. Moreover, F5446 increased 5-FU-resistant human CRC sensitivity to both 5-FU- and FasL-induced apoptosis and inhibited tumor cell growth in vitro. More importantly, F5446 suppressed human colon tumor xenograft growth in vivo. Our data indicate that pharmacological inhibition of SUV39H1 is an effective approach to suppress human CRC.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-FU; Chemoresistance; Fas; H3K9me3; Metastasis; SUV39H1

Mesh:

Substances:

Year:  2020        PMID: 32061753      PMCID: PMC7138631          DOI: 10.1016/j.canlet.2020.02.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  48 in total

1.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

2.  The epigenetic control of stemness in CD8+ T cell fate commitment.

Authors:  Luigia Pace; Christel Goudot; Elina Zueva; Paul Gueguen; Nina Burgdorf; Joshua J Waterfall; Jean-Pierre Quivy; Geneviève Almouzni; Sebastian Amigorena
Journal:  Science       Date:  2018-01-12       Impact factor: 47.728

3.  Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis.

Authors:  U von Reyher; J Sträter; W Kittstein; M Gschwendt; P H Krammer; P Möller
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

4.  Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability.

Authors:  A H Peters; D O'Carroll; H Scherthan; K Mechtler; S Sauer; C Schöfer; K Weipoltshammer; M Pagani; M Lachner; A Kohlmaier; S Opravil; M Doyle; M Sibilia; T Jenuwein
Journal:  Cell       Date:  2001-11-02       Impact factor: 41.582

5.  S-phase arrest and apoptosis induced in normal mammary epithelial cells by a novel retinoid.

Authors:  Y Zhang; A K Rishi; M I Dawson; R Tschang; L Farhana; M Boyanapalli; U Reichert; B Shroot; E C Van Buren; J A Fontana
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

6.  Epigenetic changes in tumor Fas levels determine immune escape and response to therapy.

Authors:  Heather L Maecker; Zhong Yun; Holden T Maecker; Amato J Giaccia
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

7.  Fas function and tumor progression: use it and lose it.

Authors:  Laurie B Owen-Schaub
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

8.  Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.

Authors:  Barbara Fingleton; Kathy J Carter; Lynn M Matrisian
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

Review 9.  CD95(APO-1/Fas)-mediated apoptosis: live and let die.

Authors:  P H Krammer
Journal:  Adv Immunol       Date:  1999       Impact factor: 3.543

10.  H3K9me3 facilitates hypoxia-induced p53-dependent apoptosis through repression of APAK.

Authors:  M M Olcina; K B Leszczynska; J M Senra; N F Isa; H Harada; E M Hammond
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

View more
  11 in total

Review 1.  Lysine methyltransferase inhibitors: where we are now.

Authors:  Alessandra Feoli; Monica Viviano; Alessandra Cipriano; Ciro Milite; Sabrina Castellano; Gianluca Sbardella
Journal:  RSC Chem Biol       Date:  2021-12-13

2.  LncRNA HOTAIR promotes the proliferation and invasion/metastasis of breast cancer cells by targeting the miR-130a-3p/Suv39H1 axis.

Authors:  Wenxing He; Dongmei Li; Xiaofang Zhang
Journal:  Biochem Biophys Rep       Date:  2022-05-18

3.  Fast H3K9 methylation promoted by CXCL12 contributes to nuclear changes and invasiveness of T-acute lymphoblastic leukemia cells.

Authors:  Elena Madrazo; Raquel González-Novo; Cándido Ortiz-Placín; Mario García de Lacoba; África González-Murillo; Manuel Ramírez; Javier Redondo-Muñoz
Journal:  Oncogene       Date:  2022-01-08       Impact factor: 8.756

4.  SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer.

Authors:  Li Zhang; Sijuan Tian; Minyi Zhao; Ting Yang; Shimin Quan; Qing Yang; Lihua Song; Xiaofeng Yang
Journal:  Cancer Cell Int       Date:  2020-07-20       Impact factor: 5.722

5.  H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth.

Authors:  Chunwan Lu; Dafeng Yang; John D Klement; Yolonda L Colson; Nicholas H Oberlies; Cedric J Pearce; Aaron H Colby; Mark W Grinstaff; Zhuoqi Liu; Huidong Shi; Han-Fei Ding; Kebin Liu
Journal:  Oncogene       Date:  2022-03-30       Impact factor: 8.756

6.  Cytotoxicity and growth-inhibiting activity of Astragalus polysaccharides against breast cancer via the regulation of EGFR and ANXA1.

Authors:  Wenfang Li; Xueyan Hu; Yanjie Li; Kedong Song
Journal:  J Nat Med       Date:  2021-05-27       Impact factor: 2.343

Review 7.  Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression.

Authors:  Nirmalya Saha; Andrew G Muntean
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-26       Impact factor: 10.680

Review 8.  Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.

Authors:  Vesna Risso; Elodie Lafont; Matthieu Le Gallo
Journal:  Cell Death Dis       Date:  2022-03-17       Impact factor: 9.685

9.  Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells.

Authors:  Mijin Park; Byul Moon; Jong-Hwan Kim; Seung-Jin Park; Seon-Kyu Kim; Kihyun Park; Jaehoon Kim; Seon-Young Kim; Jeong-Hoon Kim; Jung-Ae Kim
Journal:  Mol Cells       Date:  2022-08-05       Impact factor: 4.250

10.  Restoring FAS Expression via Lipid-Encapsulated FAS DNA Nanoparticle Delivery Is Sufficient to Suppress Colon Tumor Growth In Vivo.

Authors:  Alyssa D Merting; Dakota B Poschel; Chunwan Lu; John D Klement; Dafeng Yang; Honglin Li; Huidong Shi; Eric Chapdelaine; Mitzi Montgomery; Michael T Redman; Natasha M Savage; Asha Nayak-Kapoor; Kebin Liu
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.